/

Other

/

Idorsia

Idorsia

Idorsia

Verified Nov 2026

Other

·

Switzerland flag

Allschwil, Basel-Landschaft

·

Since 2017

Idorsia is a Swiss biopharmaceutical company founded in 2017 and headquartered in Allschwil, near Basel. The company operates in the 500–1,000 employee range with estimated revenue of $250–500 million. Idorsia discovers, develops, and commercializes small-molecule drugs targeting the central nervous system, cardiovascular disorders, immunological conditions, and orphan diseases. The company's approved product Quviviq treats insomnia, and it maintains a pipeline including Aprocitentan for resistant hypertension and other compounds in clinical development.

Idorsia

Verified Nov 2026

AT A GLANCE

Founded

2017

Headquarters

Switzerland flag

Allschwil, Basel-Landschaft

Employees

500-1,000

Ownership

Idorsia at a glance

Revenue

$250-500M

Est. band

Employees

500-1,000

Founded

2017

Headquarters

Allschwil, Basel-Landschaft

Industries

Automotive

Electric Vehicles

Medical

Industrial Equipment

Overview

Idorsia is a Swiss biopharmaceutical company founded in 2017 and headquartered in Allschwil, near Basel. The company operates in the 500–1,000 employee range with estimated revenue of $250–500 million. Idorsia discovers, develops, and commercializes small-molecule drugs targeting the central nervous system, cardiovascular disorders, immunological conditions, and orphan diseases. The company's approved product Quviviq treats insomnia, and it maintains a pipeline including Aprocitentan for resistant hypertension and other compounds in clinical development.

At a glance

Attribute

Detail

Founded

2017

Headquarters

Allschwil, Basel-Landschaft

Employees

500-1,000

Revenue

$250-500M (estimated)

What Idorsia makes

The company develops small-molecule therapeutics spanning central nervous system disorders, cardiovascular disease, immunological conditions, and orphan diseases, with a marketed product and multiple late-stage investigational compounds.

Latest developments

Company details

Idorsia announced a strategic partnership with Jamjoom Pharma in 2026, expanding its commercial reach in targeted markets. Idorsia was founded in 2017, has an estimated 500-1,000 employees, and is headquartered in Allschwil, Basel-Landschaft.

Frequently asked questions

What does Idorsia do?

Idorsia is a Swiss biopharmaceutical company founded in 2017 and headquartered in Allschwil, near Basel. The company operates in the 500–1,000 employee range with estimated revenue of $250–500 million. Idorsia discovers, develops, and commercializes small-molecule drugs targeting the central nervous system, cardiovascular disorders, immunological conditions, and orphan diseases. The company's approved product Quviviq treats insomnia, and it maintains a pipeline including Aprocitentan for resistant hypertension and other compounds in clinical development.

Where is Idorsia headquartered?

Idorsia is headquartered in Allschwil, Basel-Landschaft (91 Hegenheimermattweg, Allschwil, Basel-Landschaft, 4123).

When was Idorsia founded?

Idorsia was founded in 2017.

How big is Idorsia?

Idorsia has an estimated 500-1,000 employees, with revenue in the $250-500M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Allschwil, Basel-Landschaft (HQ)Headquarters · Switzerland
Allschwil, Basel-Landschaft (HQ)91 Hegenheimermattweg, Allschwil, Basel-Landschaft, 4123, SwitzerlandHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.